USE OF MATRIX METALLOPROTEASE INHIBITORS FOR THE TREATMENT OF CANCER

摘要

The invention relates to the use of an active agent, particularly an inhibitor, in treating cancer by influencing, preferably inhibiting the expression of matrix-metalloproteases. The targets for this active agent can especially relate to downstream regulators of the matrix-metalloprotease 9 (MMP-9) signal transduction pathway. According to the invention, expecially inhibitors of p38beta and p38gamma as also of mitogen-activated kinase kinase 6 (MKK6) and mitogen-activated kinase kinase 3 (MKK3) can be applied.